<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of uterine leiomyosarcoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of uterine leiomyosarcoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of uterine leiomyosarcoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martee L Hensley, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mario M Leitao, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uterine leiomyosarcoma (LMS) is a rare uterine malignancy that arises from the smooth muscle of the uterine wall. Compared with other types of uterine cancers, LMS is an aggressive tumor associated with a high risk of recurrence and death, regardless of stage at presentation [<a href="#rid1">1</a>]. Tumor grade and other histologic features can influence clinical behavior of the tumors and may be important determinants of treatment recommendations. Whenever possible, patients with uterine sarcomas should be referred to specialty centers with expertise in their diagnosis and management.</p><p>This topic will cover the treatment approach to high-grade uterine LMS. The classification, clinical manifestations, diagnosis, and staging of other uterine sarcomas are covered separately. Treatment of other types of uterine sarcomas is also covered separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3211.html" rel="external">"Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7743.html" rel="external">"Overview of the initial treatment of metastatic soft tissue sarcoma"</a>.)</p><p></p><p class="headingAnchor" id="H107273789"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>In most cases, the diagnosis of uterine LMS is made following hysterectomy or myomectomy for presumed benign uterine leiomyomas [<a href="#rid2">2,3</a>]. As an example, in one series of 106 patients with uterine sarcoma, 65 percent of those with LMS were preoperatively diagnosed with a benign leiomyoma [<a href="#rid3">3</a>]. The sequence of events leading to the diagnosis may influence the treatment approach.</p><p>The diagnosis of LMS and differentiating benign leiomyomas from LMS are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"</a> and  <a class="medical medical_review" href="/d/html/3211.html" rel="external">"Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H12821860"><span class="h2">Preoperative or intraoperative diagnosis</span><span class="headingEndMark"> — </span>LMS is typically diagnosed postoperatively, but in rare cases it is diagnosed with endometrial sampling preoperatively or with frozen section intraoperatively. There is no single preoperative test that can reliably differentiate benign from malignant uterine disease. (See  <a class="medical medical_review" href="/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Diagnostic methods'</a>.)</p><p class="headingAnchor" id="H107273603"><span class="h3">Disease confined to the uterus</span><span class="headingEndMark"> — </span>For patients with uterine LMS that is confined to the uterus at time of surgery, we proceed with a total hysterectomy.</p><p>Several case series support the role of primary surgery [<a href="#rid4">4-6</a>]. In the largest series involving 46 patients with LMS, complete cytoreduction was significantly associated with disease-free survival (p = 0.03) [<a href="#rid5">5</a>].</p><p>There is no reliable method to distinguish uterine sarcoma from benign leiomyomas preoperatively, as discussed in detail above. Among patients planning surgery for one or more uterine masses that are presumed to be benign leiomyomata, the reported prevalence of uterine sarcoma ranges from 1 in 350 to 1 in 500. The risk of occult LMS was reported to be 0.2 percent (1 in 500) in the largest cohort study of patients undergoing surgery for presumed benign leiomyomata (n = 34,728) [<a href="#rid7">7</a>]. This should be taken into account when considering the approach to patients. Several retrospective studies show that patients with LMS diagnosed following uterine morcellation have a high risk for sarcomatosis on re-exploration and have poorer survival outcomes [<a href="#rid8">8-10</a>].</p><p>In 2014, the US Food and Drug Administration issued a safety alert recommending against the use of power morcellators in patients with suspected or known uterine cancer and recommending patients be informed about the risk of unexpected cancer, which could be spread by power morcellation and worsen the patient's prognosis [<a href="#rid11">11</a>]. On this basis, a reasonable approach is to avoid morcellation of the uterus in cases where there is clinical suspicion for uterine sarcoma.</p><p>A bilateral salpingo-oophorectomy (BSO) at the time of total hysterectomy is often performed, particularly for menopausal or perimenopausal patients. However, it is not clear if BSO influences survival in patients with newly diagnosed LMS. We do not perform BSO in premenopausal patients. A National Cancer Database study assessing the impact of BSO in patients with uterine-confined LMS reported that there was no difference in overall survival (OS) among patients who underwent a BSO compared with those who did not [<a href="#rid12">12</a>]. (See <a class="local">'Premenopausal patients'</a> below.)</p><p class="headingAnchor" id="H107273610"><span class="h3">Disease extending beyond the uterus</span><span class="headingEndMark"> — </span>For patients with extrauterine disease, the role of surgery is controversial. Our approach depends on whether the patient is a surgical candidate and whether or not a complete resection of disease is feasible.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with disease confined to the pelvis, but with no invasion of the bladder or rectum (stage II) or the abdomen (stage III)  (<a class="graphic graphic_table graphicRef113544" href="/d/graphic/113544.html" rel="external">table 1</a>), we perform a total hysterectomy with BSO and surgical cytoreduction of intra-abdominal and retroperitoneal disease. Although the data are limited to small patient series, an optimal cytoreduction (to no gross residual disease) is associated with improved OS compared with patients with residual disease at the end of surgery [<a href="#rid3">3,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with disease not amenable to an optimal cytoreduction or extensive widespread disease, there is no benefit to surgery. The presence of residual disease following surgery was associated with a poor prognosis compared with a complete cytoreduction [<a href="#rid5">5</a>]. In a series of 96 patients with newly diagnosed LMS and extrauterine spread, complete surgical cytoreduction resulted in a progression-free survival (PFS) improvement of 7.4 months and an OS improvement of 11.7 months [<a href="#rid13">13</a>]. The PFS improvement remained significant on multivariable testing, but not OS. In addition, surgery may delay the start of systemic treatment, especially in patients with extensive disease. Therefore, in the absence of high-quality data showing a benefit to surgical cytoreduction, we initiate medical therapy rather than surgical cytoreduction. (See <a class="local">'Metastatic disease'</a> below.)</p><p></p><p class="bulletIndent1">However, surgery may be reasonable in the following scenarios:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total hysterectomy may serve as palliation for patients experiencing significant pelvic symptoms (ie, pain or vaginal bleeding).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total hysterectomy and resection of metastatic disease may be considered for selected patients with a relatively low disease burden beyond the peritoneal cavity (eg, isolated metastatic disease in the lung or liver). Complete resection in these patients may be possible with limited morbidity. (See <a class="local">'Metastatic disease'</a> below.)</p><p></p><p class="headingAnchor" id="H193031386"><span class="h2">Postoperative diagnosis</span><span class="headingEndMark"> — </span>For patients who are diagnosed with LMS after total hysterectomy (on final pathologic review), we do not perform a second surgical procedure for the sole purpose of staging. Instead, we perform a postoperative computed tomography of the chest, abdomen, and pelvis to help guide postoperative treatment.</p><p>For patients who underwent a hysterectomy (or myomectomy) alone and who are surgical candidates, however, a second surgical procedure is reasonable in the following situations [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>If ovaries were conserved in prior surgery, we do not routinely reoperate solely to perform salpingo-oophorectomy; this is of uncertain benefit and exposes the patient to the risks of surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who underwent a supracervical hysterectomy (or myomectomy), we suggest removal of the cervix or hysterectomy with resection of any visible residual disease if possible. Concomitant BSO can also be performed in perimenopausal and menopausal patients. It is not clear that BSO in premenopausal patients is beneficial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom the tumor was morcellated, we suggest surgical exploration and staging to ensure any residual peritoneal disease is resected. The value of re-exploration after morcellation and the rapidity of spread were evaluated in a study in patients with no evidence of extrauterine disease at time of surgery who underwent morcellation and were subsequently diagnosed with uterine LMS. Re-exploration was performed immediately (within 50 days), and three of eight of these patients were upstaged to stage III or IV [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H107274757"><span class="h1">INDICATIONS FOR LYMPHADENECTOMY</span><span class="headingEndMark"> — </span>We perform a pelvic lymphadenectomy for patients if the pelvic nodes are palpably enlarged intraoperatively or there is evidence of extrauterine disease [<a href="#rid14">14,15</a>]. Patients with LMS confined to the uterus have a low incidence of lymph node involvement. This was illustrated in a Gynecologic Oncology Group study of 59 patients with clinical stage I or II LMS (all of whom underwent surgical staging) in which the incidence of lymph node metastases was less than 5 percent [<a href="#rid16">16</a>]. In another series of 37 patients with LMS who underwent nodal sampling, only three patients had positive nodes, and in all cases, they were clinically suspicious at surgery [<a href="#rid15">15</a>]. Routine lymphadenectomy should not be performed in patients with uterine LMS confined to the uterus and normal-appearing lymph nodes.</p><p class="headingAnchor" id="H522011517"><span class="h1">ROLE OF IMAGING</span><span class="headingEndMark"> — </span>Up to 33 percent of patients with newly diagnosed uterine LMS present with distant metastatic disease (stage IVB), most commonly involving the liver, lung, or upper abdomen [<a href="#rid2">2,6,14,17,18</a>]. Therefore, all patients should undergo imaging to rule out metastatic disease following pathologic confirmation of the diagnosis.</p><p>There are no data on the ideal imaging evaluation for patients with LMS. Chest radiograph, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are all used to evaluate for metastatic disease for soft tissue sarcomas. We perform a CT perioperatively in all patients diagnosed with LMS. There are no data on the utility of PET in perioperative staging of LMS, and the data on PET for the detection of recurrence are limited to retrospective case series [<a href="#rid19">19,20</a>]. There is no evidence that it provides more useful information than either CT or MRI. Further discussion on the imaging evaluation of sarcomas is covered separately. (See  <a class="medical medical_review" href="/d/html/14259.html" rel="external">"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Radiographic studies'</a>.)</p><p class="headingAnchor" id="H213141155"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Uterine LMS is surgically staged according to the 2017 International Federation of Gynecology and Obstetrics (FIGO)/Tumor, Node, Metastasis (TNM) classification system  (<a class="graphic graphic_table graphicRef113544" href="/d/graphic/113544.html" rel="external">table 1</a>). This is the same staging system that is used for endometrial stromal sarcoma but differs somewhat from the staging system for uterine adenosarcoma  (<a class="graphic graphic_table graphicRef113544" href="/d/graphic/113544.html" rel="external">table 1</a>). The difference is in the definitions for stage I; for LMS stage I, substages are defined by tumor diameter (IA: ≤5 cm; IB: &gt;5 cm). Endometrial carcinoma and carcinosarcoma use an entirely different staging system  (<a class="graphic graphic_table graphicRef141918" href="/d/graphic/141918.html" rel="external">table 2</a>). The separate staging systems for uterine sarcomas were introduced in 2010 [<a href="#rid21">21</a>].</p><p>The FIGO staging system does not predict the prognosis for overall survival for patients with uterine LMS [<a href="#rid22">22</a>]. A nomogram that incorporates patient age, tumor size, grade, local extension, distant metastases, and mitotic rate as key variables may be prognostically more useful [<a href="#rid22">22</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H9939629"><span class="h1">ADJUVANT TREATMENT</span><span class="headingEndMark"> — </span>Observation is the standard of care following resection of a uterus-limited, intact specimen. While chemotherapy or pelvic radiation is sometimes considered following surgery for LMS, no form of adjuvant therapy has demonstrated improvement in survival outcomes compared with observation.</p><p class="headingAnchor" id="H677536887"><span class="h2">Early-stage disease</span><span class="headingEndMark"> — </span>For patients with early-stage (stage I or II) uterine LMS, there is evidence that intervention does not improve the survival outcomes compared with postsurgical surveillance [<a href="#rid23">23-26</a>]. Therefore, for patients with surgical stage I or II LMS, we suggest observation as the standard management rather than adjuvant therapy. A prospective, randomized trial was conducted by the Gynecologic Oncology Group (GOG) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) and Cancer Research UK, which compared the regimen from SARC 005 with observation in patients who had undergone surgical resection of high-grade International Federation of Gynecology and Obstetrics (FIGO) stage I uterine LMS (GOG 277) [<a href="#rid27">27</a>]. This study closed after enrollment of 38 patients due to slow accrual. Nevertheless, the data showed that the same number of recurrences were seen in both arms, there was not statistical improvement in progression-free survival (PFS), and overall survival (OS) was worse in the chemotherapy-treatment arm. These data support the conclusion that observation is the standard of care for this population [<a href="#rid27">27</a>].</p><p>The data evaluating chemotherapy and radiation therapy (RT) for early-stage LMS are discussed below.</p><p class="headingAnchor" id="H28816387"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a>, combination chemotherapy, and RT have been evaluated as adjuvant treatment for patients with early-stage disease. However, the lack of benefits of a treatment with associated morbidity must be considered.</p><p class="headingAnchor" id="H28815849"><span class="h4">Doxorubicin</span><span class="headingEndMark"> — </span>The GOG conducted a phase III trial in 156 patients with stage I or II uterine sarcoma (all histologies) who were randomly assigned treatment with postoperative <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> or no further treatment [<a href="#rid23">23</a>]. Although patients treated with doxorubicin had a lower recurrence rate compared with those not treated with chemotherapy (41 versus 53 percent), this was not statistically significant. In addition, adjuvant doxorubicin had no impact on PFS or OS.</p><p class="headingAnchor" id="H28815963"><span class="h4">Docetaxel and gemcitabine</span><span class="headingEndMark"> — </span>Although not composed exclusively of patients with early-stage disease, fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (900 mg/m<sup>2</sup> over 90 minutes on days 1 and 8) plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (75 mg/m<sup>2</sup> on day 8) administered with hematopoietic growth factor support was evaluated in a trial involving 25 patients with completely resected, high-grade uterine LMS [<a href="#rid24">24</a>]. Among patients with stage I or II disease, 59 percent remained progression free at three years (median, 39 months). Of note, at a median follow-up of 49 months, the two-year PFS rate was 45 percent, and median PFS was 13 months for the entire cohort. Given the lack of a control arm and the small number of patients treated, the significance of these findings is not clear.</p><p><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> therapy was not associated with a survival advantage in a retrospective study of 111 patients with stage I uterine LMS [<a href="#rid28">28</a>]. The 33 patients treated with gemcitabine-docetaxel had similar three-year disease-free survival compared with the 77 patients who did not receive adjuvant chemotherapy (three-year PFS, 45 versus 53 percent). The three-year OS rates were also similar (59 versus 66 percent). These data support surveillance/observation for patients with stage I, uterus-limited LMS rather than chemotherapy [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H28816005"><span class="h4">Docetaxel and gemcitabine followed by doxorubicin</span><span class="headingEndMark"> — </span>A prospective, multi-institutional phase II trial (SARC 005) enrolled 47 patients with uterus-limited, high-grade LMS [<a href="#rid30">30</a>]. All patients received four cycles of fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, followed by four cycles of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> and were evaluated for disease recurrence by imaging approximately every three months. Of those enrolled, 89 percent of patients received all eight planned cycles. The median time to recurrence was 27 months, and the three-year PFS rate was 57 percent. As detailed above, the randomized trial comparing this regimen with observation did not show improvement in recurrence rates or survival outcomes. (See <a class="local">'Early-stage disease'</a> above.)</p><p class="headingAnchor" id="H28815876"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>The use of adjuvant RT has no impact on survival outcomes for patients with early-stage LMS. This was demonstrated in an EORTC randomized trial (EORTC 55874), which enrolled patients with stage I and II uterine sarcomas and randomly assigned them to treatment with postoperative RT or observation [<a href="#rid26">26</a>]. Among patients with LMS (n = 103), pelvic RT resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>No significant differences in either local or distant progression rates compared with observation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trend toward a reduction in OS (hazard ratio for survival 0.64, 95% CI 0.36-1.14), although this did not reach statistical significance</p><p></p><p class="headingAnchor" id="H28815942"><span class="h2">Advanced disease</span><span class="headingEndMark"> — </span>Patients with intra-abdominal involvement of disease (stage III) or distant metastases (stage IV) who have undergone complete resection of disease have a high risk of disease progression following surgery alone. Therefore, postresection chemotherapy may be offered, rather than observation, although whether treatment improves survival has not been established. Thus, surveillance is also a reasonable alternative to chemotherapy.</p><p class="headingAnchor" id="H107273754"><span class="h3">Docetaxel and gemcitabine</span><span class="headingEndMark"> — </span>Only one prospective study evaluated chemotherapy following a complete cytoreduction for uterine LMS. As discussed above, 25 patients with stage I to IV LMS received <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> on a GOG trial [<a href="#rid24">24</a>]. However, this study lacked a control arm, and it remains unclear whether treatment results in an improvement in survival. (See <a class="local">'Docetaxel and gemcitabine'</a> above.) </p><p class="headingAnchor" id="H677536961"><span class="h3">Combined-modality treatment</span><span class="headingEndMark"> — </span>For patients with advanced LMS, the administration of combined-modality treatment (eg, pelvic radiation plus chemotherapy) remains investigational. One study randomly assigned 81 patients with uterine sarcoma (53 with LMS) to treatment with pelvic RT with or without combination chemotherapy using <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (API) [<a href="#rid31">31</a>]. Compared with pelvic RT, the addition of API was associated with the following nonstatistically significant trends:</p><p class="bulletIndent1"><span class="glyph">●</span>A lower incidence of recurrence (39 versus 62 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher PFS at three years (52 versus 41 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in OS at three years (80 versus 67 percent)</p><p></p><p>Treatment with API was associated with serious (grade 3/4) toxicity, including neutropenia (84 percent), febrile neutropenia (22 percent), and nausea and vomiting (24 percent). Two treatment-related deaths due to febrile neutropenia also occurred. The study was closed early due to poor accrual. Until further data become available, the administration of combined-modality treatment should be considered investigational.</p><p class="headingAnchor" id="H12824634"><span class="h1">POST-TREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>Uterine LMS is an aggressive tumor with a high risk of relapse, even when confined to the uterus at diagnosis [<a href="#rid1">1</a>]. Therefore, we perform a physical exam every three to four months and chest, abdomen, and pelvic imaging every three to four months for two to three years, then every 6 to 12 months for the next two years. There are no data defining the optimal frequency or duration of surveillance imaging. Although there are no data that surveillance improves survival outcomes for patients with LMS, these recommendations are consistent with surveillance guidelines of the National Comprehensive Cancer Network [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H12824641"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with LMS have a poor prognosis regardless of stage [<a href="#rid17">17,33</a>]. In a large study of 1396 patients with LMS (71 percent with stage I/II disease), the five-year disease-specific survival (DSS) was 66 percent [<a href="#rid17">17</a>]. Stratified by stage, the five-year disease-specific overall survival (OS) for stage I, II, III, and IV disease was 76, 60, 45, and 29 percent, respectively. Factors associated with worse DSS were:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher tumor grade (hazard ratio [HR] 1.83, 95% CI 1.43-2.34)</p><p class="bulletIndent1"><span class="glyph">●</span>Higher disease stage (HR 1.58, 95% CI 1.47-1.71)</p><p class="bulletIndent1"><span class="glyph">●</span>African American race (HR 1.45, 95% CI 1.09-1.94)</p><p></p><p>Despite the prognostic significance of grade, there is no single, universally accepted grading system for uterine LMS. Low-grade LMS and smooth muscle neoplasms that do not meet diagnostic criteria for uterine LMS (eg, smooth muscle tumors of uncertain malignant potential) likely have a more favorable disease course. Classification and grading of uterine smooth muscle tumors can be challenging, thus specialized pathology review is recommended. (See  <a class="medical medical_review" href="/d/html/3211.html" rel="external">"Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis", section on 'Leiomyosarcoma'</a>.)</p><p>Neither International Federation of Gynecology and Obstetrics (FIGO) nor American Joint Committee on Cancer (AJCC) staging performs well in terms of providing prognostic information for OS in uterine LMS [<a href="#rid22">22</a>]. A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mskcc.org%2Fnomograms%2Futerine&amp;token=P5Od9O29Gx2epFPupdzNG2%2FAT%2Fb4L8s93F%2BUEd1xOql7czY2ce8r2AQtQCb9axqa&amp;TOPIC_ID=3188" target="_blank">nomogram</a> has been developed that incorporates patient age, tumor size, grade, local extension, distant metastases, and mitotic rate as key variables. This nomogram performs better than FIGO and AJCC staging in terms of predicting five-year OS [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H3029356502"><span class="h1">ROLE OF MOLECULAR DIAGNOSTIC TESTING AND SOMATIC TUMOR PROFILING</span><span class="headingEndMark"> — </span>While some soft tissue sarcomas are associated with diagnostic chromosomal translocations or characteristic gene mutations, this is not the case for uterine LMS. Uterine LMS commonly have multiple chromosomal abnormalities associated with chromothripsis. They frequently harbor inactivating mutations in tumor protein p53 (<em>TP53</em>), retinoblastoma gene (<em>RB1</em>), and/or have whole-genome duplication [<a href="#rid35">35</a>]. Based on available data, these genetic alterations and mutations are not considered therapeutically actionable. Microsatellite instability and/or high tumor mutational burden are distinctly uncommon in uterine LMS, perhaps explaining the lack of activity of immunotherapy agents observed in phase II trials in LMS [<a href="#rid36">36,37</a>].</p><p>While there is not an established role for routine use of next-generation sequencing of uterine LMS, in some cases the information may have implications for diagnostic precision and/or therapies. For example, somatic alterations in breast cancer susceptibility gene 2 (<em>BRCA2</em>) have been reported in 5 to 8 percent of uterine LMS, and responses to poly(ADP-ribose) polymerase (PARP) inhibition have been observed among patients with homozygous <em>BRCA2</em>-altered uterine LMS treated on clinical trials that included PARP inhibitor therapy [<a href="#rid38">38</a>]. Similarly, next-generation sequencing and/or RNA-based fusion mutation testing may provide useful diagnostic precision in uterine sarcomas with nonclassical histologic appearance (epithelioid and myxoid findings, for example), which could have import for treatment choices and clinical trial eligibility [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H107274051"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H107274058"><span class="h2">Premenopausal patients</span><span class="headingEndMark"> — </span>Premenopausal patients with uterine LMS may wish to retain their ovaries for fertility preservation. In addition, oophorectomy in these patients will result in premature menopause, which may impact quality of life.</p><p>Most experts perform a bilateral salpingo-oophorectomy (BSO) as part of standard surgical treatment. However, data are limited regarding the impact of BSO on LMS survival. At least 40 percent of uterine LMS express estrogen and/or progesterone receptors [<a href="#rid41">41-43</a>]. However, in one study of 341 patients who were &lt;50 years old and had stage I or II disease at diagnosis, there was no difference in five-year disease-free survival in those who did or did not undergo BSO [<a href="#rid17">17</a>]. This study was limited because the number of patients who had previously had both ovaries removed was not reported. As mentioned above, a larger National Cancer Database study assessing the impact of BSO in 1076 patients with uterine-confined LMS also reported that there was no difference in overall survival among patients who underwent a BSO compared with those who did not [<a href="#rid12">12</a>].</p><p>In the absence of randomized trial data addressing the impact of BSO on survival in LMS, recommendations regarding BSO must be individualized. Some may reasonably recommend BSO for patients whose International Federation of Gynecology and Obstetrics stage I uterine LMS is estrogen and/or progesterone receptor positive. However, there have not been any reports suggesting that such an approach will improve outcomes. The correlation of expression of estrogen receptor and/or progesterone receptor and performing BSO is speculative at this time.</p><p class="headingAnchor" id="H107274094"><span class="h2">Medically inoperable patients</span><span class="headingEndMark"> — </span>The approach to patients who are not candidates for surgical resection due to comorbidity or poor performance status must be individualized. Given the poor prognosis for patients with uterine LMS regardless of stage, nonsurgical treatment is palliative, not curative. Therefore, careful consideration of the benefits (eg, control of pain or bleeding) must be weighed against the toxicities of medical treatment. The treatment approach to medically inoperable patients mirrors that of patients with metastatic disease. (See <a class="local">'Metastatic disease'</a> below.)</p><p class="headingAnchor" id="H12822947"><span class="h1">LOCAL RECURRENCE OR OLIGOMETASTATIC DISEASE</span><span class="headingEndMark"> — </span>For patients with localized recurrences or limited metastatic disease, surgical resection may offer a survival advantage and should be offered to appropriately selected patients. However, the data supporting this approach are limited to small series [<a href="#rid44">44-46</a>]. In one series of 31 patients with pulmonary metastases, for example, metastasectomy resulted in a median overall survival (OS) of 70 months.</p><p>The best candidates for this approach are those who recur after a prolonged progression-free interval (at least 12 to 18 months) and with an isolated site of recurrence that is amenable to complete resection. (See  <a class="medical medical_review" href="/d/html/7738.html" rel="external">"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma"</a>.)</p><p>For patients who are not surgical candidates, radiation therapy is an alternative treatment option for locally recurrent disease. Its application in uterine sarcomas is similar to the approach in endometrial adenocarcinomas. (See  <a class="medical medical_review" href="/d/html/3186.html" rel="external">"Management of locoregional recurrence of endometrial cancer", section on 'Those with no prior radiation'</a>.)</p><p>Another approach to localized metastatic disease is radiofrequency ablation (RFA). Although no randomized trials have been performed, RFA may successfully treat individual lesions that are small (generally under 4 cm) and accessible (generally not near major blood vessels) [<a href="#rid47">47</a>]. Appropriate candidates for RFA have single-site disease that is accessible for ablation and has recurred after a prolonged disease-free interval.</p><p>Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of complete surgical cytoreduction has gained attention in the management of multiple malignancies with intraperitoneal metastases. A small, retrospective series of 26 patients with recurrent uterine sarcoma (22 with LMS) did not find statistically significant differences in progression-free survival or OS comparing patients who underwent surgery and HIPEC and those who underwent surgery but not HIPEC [<a href="#rid48">48</a>]. The authors suggest there may be a benefit with HIPEC, but this is speculation. The use of HIPEC in patients with uterine LMS outside of a clinical trial cannot be justified at this time.</p><p class="headingAnchor" id="H12822955"><span class="h1">METASTATIC DISEASE</span><span class="headingEndMark"> — </span>Uterine LMS most commonly metastasizes to the lungs, liver, abdomen, and pelvis [<a href="#rid49">49</a>]. Bone and brain metastases are less common sites of involvement. For patients with metastatic disease that is not amenable to complete surgical resection, treatment is given with palliative intent. Chemotherapy is a reasonable option for patients with metastatic LMS who maintain a good performance status and in whom organ function permits the use of cytotoxic chemotherapy. For other patients, we suggest palliative care. (See  <a class="medical medical_review" href="/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care"</a>.)</p><p>Although there is no widely agreed upon agent or regimen, there is sufficient activity of chemotherapy to support its use in patients with unresectable, recurrent disease [<a href="#rid50">50</a>]. Of the available options, we favor fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> because of the high objective response rates demonstrated in prospective clinical trials as a first- or second-line therapy and because of superiority of the gemcitabine-docetaxel combination over gemcitabine alone in a randomized trial for soft tissue sarcoma [<a href="#rid51">51</a>]. <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> is also a reasonable first-line choice. For patients who progress after first-line therapy, further treatment is based on patient preference, organ function, and performance status.</p><p>In general, management of recurrent uterine sarcoma is similar to treatment of metastatic soft tissue sarcomas arising at other sites, although some data suggest that uterine LMS may be more sensitive to some chemotherapy regimens than other non-LMS histology soft tissue sarcomas [<a href="#rid6">6,32</a>]. (See  <a class="medical medical_review" href="/d/html/7738.html" rel="external">"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma"</a>.)</p><p class="headingAnchor" id="H107274208"><span class="h2">Preferred options for first-line therapy</span></p><p class="headingAnchor" id="H2299104652"><span class="h3">Gemcitabine plus docetaxel</span><span class="headingEndMark"> — </span>The combination of fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> has been evaluated as a first- and second-line treatment for metastatic uterine LMS and is our preferred first-line regimen. <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> is also a reasonable first-line choice. (See <a class="local">'Doxorubicin'</a> below.)</p><p>Data in support of fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span>In Gynecologic Oncology Group (GOG) 87L, 42 patients were treated with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> until disease progression or unacceptable toxicity. The overall response rate (ORR) was 36 percent [<a href="#rid52">52</a>]. The major toxicity was myelosuppression, with grade 3 or 4 neutropenia occurring in 17 to 20 percent of patients. Other side effects included fatigue (74 percent), gastrointestinal complaints (14 percent), and pulmonary toxicity (9 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In GOG 131G, 51 patients who had disease progression after first-line treatment (90 percent had received <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>) received <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid53">53</a>]. The ORR was 27 percent, and 52 percent were progression free at six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In GOG 0250, a phase III trial of gemcitabine-docetaxel plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or placebo, the addition of bevacizumab failed to improve response rate, response duration, progression-free survival (PFS), or overall survival (OS). Objective response rates in both arms of this study were similar to those observed in the first-line, phase II study of gemcitabine-docetaxel. Some patients had sustained responses even after stopping active cytotoxic therapy [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H251318377"><span class="h3">Doxorubicin</span><span class="headingEndMark"> — </span>For patients with good venous access or central venous access and normal cardiac function, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (75 mg/m<sup>2</sup> every three weeks) is a reasonable first-line alternative to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> for metastatic LMS. Doxorubicin is also a reasonable second-line treatment choice for patients who received gemcitabine-docetaxel as first-line treatment.</p><p>A phase III randomized trial compared fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> versus <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> as first-line treatment for metastatic sarcoma (of any site or histology) [<a href="#rid55">55</a>]. Twenty-seven percent of patients had LMS, site of origin not specified. The regimens were similar in terms of response rates and PFS.</p><p>In one GOG study, 104 chemotherapy-naïve patients were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> with or without <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (500 mg/m<sup>2</sup>) [<a href="#rid56">56</a>]. The ORR was 19 percent in both arms. OS was also similar (median, 12 months with doxorubicin versus 11 months with the combination).</p><p>The combination of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> and <a class="drug drug_general" data-topicid="110540" href="/d/drug information/110540.html" rel="external">olaratumab</a> showed benefit over doxorubicin alone for advanced soft tissue sarcoma in one phase II trial, but not in the confirmatory phase III trial. Olaratumab was removed from the market following the negative phase III study results. These data are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7743.html" rel="external">"Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'Doxorubicin'</a>.) </p><p class="headingAnchor" id="H209009155"><span class="h4">In combination with trabectedin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> plus <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a> followed by trabectedin regimen may be appropriate first-line treatment for patients with LMS:</p><p class="bulletIndent1"><span class="glyph">●</span>Who are fit, have excellent organ function, are likely able to sustain the high risk for clinically significant toxicities, <strong>and</strong>,</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In whom rapid objective response is clinically needed and/or in whom objective response is likely to make a subsequent complete gross resection possible.</p><p></p><p>The combination of intravenous <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (60 mg/m<sup>2</sup>) plus intravenous <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a> (1.1 mg/m<sup>2</sup> over three hours) once every three weeks for up to six cycles followed by maintenance with trabectedin was compared with doxorubicin 75 mg/m<sup>2</sup> once every three weeks for up to six cycles followed by observation in a randomized trial [<a href="#rid57">57</a>]. The doxorubicin-trabectedin followed by trabectedin arm had longer PFS compared with six cycles of doxorubicin followed by observation, but with greater toxicity.</p><p>In a non-blinded, randomized trial including 150 patients with metastatic LMS of uterine or nonuterine soft tissue sarcoma origin, doxorubicin-trabectedin followed by <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a> improved PFS relative to <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> alone (12.2 versus 6.2 months, adjusted hazard ratio 0.41, 95% CI 0.29-0.58), as well as objective response rates (36 versus 13 percent) [<a href="#rid57">57</a>]. Among the 67 patients with uterine LMS, the trabectedin group also experienced improved PFS (10.0 versus 4.1 months, HR 0.46, 95% CI 0.27-0.78) and objective response rates (36 versus 15 percent). However, toxicities were higher with the combination. The most common grade ≥3 adverse events were neutropenia (80 percent with trabectedin plus doxorubicin versus 13 percent with doxorubicin alone), anemia (31 versus 5 percent), thrombocytopenia (47 versus 0 percent]), and febrile neutropenia (28 versus 9 percent).</p><p>Some important issues for consideration in interpretation of these data include that more patients in the <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> arm had bone metastases, and fewer patients had grade 1 tumors compared with the doxorubicin-trabectedin arm. Since the study was unblinded, there is the potential for bias in the timing of imaging such that patients on observation may have been imaged sooner. More patients in the doxorubicin-trabectedin arm underwent surgery following six cycles of treatment than in the doxorubicin arm (20 versus 8 percent), a decision which may have been influenced by potential bias and/or by the presence of bone metastases, and which complicates the interpretation of the observed PFS difference in the whole cohort.</p><p>Furthermore, it is important to note that this was a first-line treatment study; there are no available data to demonstrate whether this regimen would be tolerable as a later line of therapy, nor whether it would have the same PFS advantage.</p><p class="headingAnchor" id="H83859308"><span class="h2">Alternatives and subsequent-line options</span></p><p class="headingAnchor" id="H107274217"><span class="h3">Doxorubicin</span><span class="headingEndMark"> — </span>For patients who did not receive front-line doxorubicin-based treatment, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> may be administered in the second line. (See <a class="local">'Doxorubicin'</a> above.)</p><p class="headingAnchor" id="H14240591"><span class="h3">Pegylated liposomal doxorubicin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">Pegylated liposomal doxorubicin</a> (50 mg/m<sup>2</sup> intravenous therapy [IV] every four weeks) may be a reasonable choice for patients with a lower disease burden and no impending organ dysfunction, since in such patients achieving stable disease with less toxicity may be the objective. Most patients do not require central venous access, and most do not experience alopecia. Pegylated liposomal doxorubicin achieved objective response in 16 percent of patients with uterine LMS as first-line therapy in a phase II trial of 35 patients. Although this response rate is lower than what one would expect with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, pegylated liposomal doxorubicin is better tolerated [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H107274224"><span class="h3">Gemcitabine</span><span class="headingEndMark"> — </span>Some patients with lower disease burden and without impending organ dysfunction may achieve disease control with single-agent <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (1000 mg/m<sup>2</sup> IV over 30 minutes on a three-week on/one-week off schedule) with less toxicity than with fixed-dose-rate gemcitabine and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>. A randomized trial showed higher response rates, longer PFS, and improved OS for fixed-dose-rate gemcitabine plus docetaxel compared with gemcitabine alone in patients with soft tissue sarcomas [<a href="#rid51">51</a>]; however, gemcitabine has shown an ORR of 20 percent as single-agent therapy [<a href="#rid59">59</a>]. Serious (grade 4) toxicity consists of neutropenia (16 percent), nausea and vomiting (4.5 percent), and rash (2.3 percent).</p><p class="headingAnchor" id="H107274436"><span class="h3">Ifosfamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a> (1.5 g/m<sup>2</sup> IV for five days with <a class="drug drug_general" data-topicid="9615" href="/d/drug information/9615.html" rel="external">mesna</a>, every three weeks) was evaluated in a GOG study of 56 patients and resulted in an ORR of 17 percent [<a href="#rid60">60</a>]. A second GOG study evaluated ifosfamide plus <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> that resulted in a 30 percent ORR, although the duration of response was only four months [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H107274250"><span class="h3">Trabectedin (as a single agent)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">Trabectedin</a> (1.5 mg/m<sup>2</sup> IV over 24 hours every three weeks) is a rational second- or third-line treatment option for patients with LMS who have previously received anthracycline therapy [<a href="#rid62">62-67</a>]. It is approved for use in Europe, the United States, and other countries for advanced liposarcoma and LMS after progression on an anthracycline-based treatment. Trabectedin is given via central venous access, and requires a normal cardiac ejection fraction.</p><p>In a phase III trial, patients with liposarcoma or LMS whose tumors had progressed after prior anthracycline therapy were randomized 2:1 to <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a> versus <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>. PFS was 4.2 months among patients treated with trabectedin compared with 1.5 months among those treated with dacarbazine. Objective response rates were low in both arms: 9.9 percent for trabectedin versus 6.9 percent for dacarbazine [<a href="#rid62">62</a>]. In a phase II GOG study that enrolled 20 patients with metastatic uterine LMS and who were treatment naïve, only two responses were observed; however, median PFS was 5.8 months [<a href="#rid63">63</a>]. A retrospective study of 66 patients with previously treated LMS reported an ORR of 16 percent [<a href="#rid64">64</a>]. However, median PFS was only three months.</p><p><a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">Trabectedin</a> has also been evaluated as part of a combination therapy. For example, a single-arm phase II trial performed by the French Sarcoma Group evaluated trabectedin (administered as a three-hour infusion) in combination with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> as a first-line treatment for advanced or metastatic LMS (of uterine or soft tissue origin) [<a href="#rid65">65</a>]. Among the cohort with uterine LMS (n = 48), the ORR was 59.6 percent. Grade 3 or 4 neutropenia occurred in 78 percent of patients and grade 3 or 4 thrombocytopenia in 37 percent. Febrile neutropenia occurred in 24 percent of patients. In a subsequent, randomized, phase II trial for trabectedin plus doxorubicin versus doxorubicin alone as first-line treatment for soft tissue sarcoma, there was no difference in response rates (17 percent in each arm) or PFS (approximately 5.5 months in each arm), and toxicities were greater with the combination treatment [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H107274236"><span class="h3">Dacarbazine and temozolomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">Dacarbazine</a> (1200 mg/m<sup>2</sup> every three weeks) has modest activity in soft tissue sarcomas [<a href="#rid68">68</a>]. In addition, <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> (50 to 75 mg/m<sup>2</sup> taken orally every day for six out of eight weeks), an oral prodrug of dacarbazine, also appears to be active, although the data are quite limited [<a href="#rid69">69,70</a>]. Prospective phase III data have shown that <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a> is superior to dacarbazine in patients with liposarcoma or LMS who have previously received anthracycline-based therapy.</p><p class="headingAnchor" id="H463025574"><span class="h3">Pazopanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">Pazopanib</a> (800 mg once daily), an oral multikinase inhibitor, may be a reasonable option for patients with good gastrointestinal function and who are not considered high risk for pulmonary hemorrhage or intestinal perforation. It is approved in the United States for the treatment of metastatic soft tissue sarcomas after disease progression on an anthracycline-based therapy. The European Organisation for Research and Treatment of Cancer conducted a phase III trial that included 372 patients who were randomly assigned to treatment with pazopanib or placebo [<a href="#rid71">71</a>]. Compared with placebo, pazopanib resulted in an improvement in median PFS (5 versus 2 months; hazard ratio [HR] 0.31, 95% CI 0.24-0.40) but no significant difference in median OS (13 versus 11 months; HR 0.86, 95% CI 0.67-1.11). The objective response rate to pazopanib was 6 percent [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H443224920"><span class="h3">Eribulin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">Eribulin</a> (1.4 mg/m<sup>2</sup> IV on days 1 and 8 of a 21-day cycle), a microtubulin inhibitor, may be a reasonable choice for third- or greater-line therapy in patients who have failed prior anthracycline therapy. Eribulin was compared with <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a> in a phase III trial for patients with LMS or adipocytic sarcoma who had received two or more lines of therapy and had also received prior anthracycline therapy. There was no statistically significant difference between the two arms in terms of PFS (2.6 months in each arm) or the percentage of patients who were progression free at 12 weeks (33 versus 29 percent). Treatment with eribulin was associated with a small increase in OS (13.5 versus 11.5 months) for the overall cohort, but OS was not superior with eribulin in the LMS subset (12.8 months with eribulin versus 12.3 months with dacarbazine). In the LMS subset, PFS was 2.2 months with eribulin and 2.6 months with dacarbazine [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H107274243"><span class="h3">Endocrine therapy</span><span class="headingEndMark"> — </span>The aromatase inhibitors (<a class="drug drug_general" data-topicid="8780" href="/d/drug information/8780.html" rel="external">anastrozole</a> or <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>) have been associated with low ORR (less than 10 percent) in patients with LMS [<a href="#rid73">73-76</a>]. However, for some patients with estrogen receptor- or progesterone receptor-positive LMS, and in whom the disease burden is low and the disease pace is indolent, treatment with hormone blockade may be reasonable [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H3817662029"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>– Uterine leiomyosarcoma (LMS) is a rare and aggressive uterine malignancy that arises from the smooth muscle of the uterine wall. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – LMS is surgically staged according to the 2017 International Federation of Gynecology and Obstetrics/Tumor, Node, Metastasis classification system  (<a class="graphic graphic_table graphicRef113544" href="/d/graphic/113544.html" rel="external">table 1</a>). This is the same staging system that is used for endometrial stromal sarcoma but differs somewhat from the staging system for uterine adenosarcoma  (<a class="graphic graphic_table graphicRef113544" href="/d/graphic/113544.html" rel="external">table 1</a>). (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preoperative or intraoperative diagnosis</strong> – For patients in whom the diagnosis of LMS is made preoperatively (see <a class="local">'Preoperative or intraoperative diagnosis'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We recommend a total hysterectomy for patients with disease confined to the uterus rather than nonoperative therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest a bilateral salpingo-oophorectomy (BSO) at the time of surgery in perimenopausal and menopausal patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). There is no proven benefit of BSO in premenopausal patients. (See <a class="local">'Disease confined to the uterus'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with disease that has spread beyond the uterus but is confined to the peritoneal cavity, we suggest surgical cytoreduction (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We limit pelvic lymphadenectomy to patients with pelvic nodes that are palpably enlarged intraoperatively. (See <a class="local">'Indications for lymphadenectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative diagnosis</strong> – For patients whose hysterectomy specimen is found postoperatively to be LMS, a second surgical procedure for the sole purpose of staging is not required. Further surgical management depends upon the initial procedure and patient characteristics:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who underwent a supracervical hysterectomy (or myomectomy), we suggest removal of the cervix or hysterectomy and resection of any residual disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients in whom the tumor was morcellated at the time of surgery, we suggest surgical exploration (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), with the goal of assessing for residual disease and resection of disease if amenable to complete resection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for adjuvant therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with newly diagnosed uterine LMS that is limited to the body of the uterus, we suggest observation rather than adjuvant chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We recommend against pelvic RT in these patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Enrollment in clinical trials investigating the role of adjuvant therapy compared with observation should be encouraged. (See <a class="local">'Early-stage disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with stage III or IV LMS that is completely resected, we suggest chemotherapy rather than observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Advanced disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-treatment surveillance</strong> – For all patients with newly diagnosed LMS, surveillance examinations and imaging is recommended due to the high risk of relapse, regardless of stage. (See <a class="local">'Post-treatment surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local recurrence or metastatic disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Local recurrence or limited metastatic disease</strong> – For patients with localized recurrence or limited metastatic disease that is amenable to complete resection, we suggest surgical resection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) or consideration of local ablation techniques. (See <a class="local">'Local recurrence or oligometastatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unresectable disease</strong> – For patients with metastatic, unresectable disease, treatment is administered with palliative intent. Chemotherapy is a reasonable option for patients with metastatic LMS who maintain a good performance status and in whom organ function permits the use of cytotoxic chemotherapy. For other patients, we suggest palliative care.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with metastatic disease who are chemotherapy naïve, we suggest fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> or <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (with or without <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a>) as first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preferred options for first-line therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who progress after fixed-dose-rate <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and/or <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, the choice among chemotherapy options is based on patient preference, organ function, and performance status. For patients with hormone receptor-positive LMS, in whom the disease burden is low and the pace of disease is indolent, hormone-blockade therapy may be an alternative treatment option. (See <a class="local">'Metastatic disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2570922905"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Nadeem R Abu-Rustum, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116:131.</a></li><li><a class="nounderline abstract_t">Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89:460.</a></li><li><a class="nounderline abstract_t">Sagae S, Yamashita K, Ishioka S, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004; 67:33.</a></li><li><a class="nounderline abstract_t">Nassar OA, Abdul Moaty SB, Khalil el-SA, et al. Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst 2010; 22:113.</a></li><li><a class="nounderline abstract_t">Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol 2008; 134:1277.</a></li><li><a class="nounderline abstract_t">Dinh TA, Oliva EA, Fuller AF Jr, et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004; 92:648.</a></li><li><a class="nounderline abstract_t">Raine-Bennett T, Tucker LY, Zaritsky E, et al. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. Obstet Gynecol 2016; 127:29.</a></li><li><a class="nounderline abstract_t">Einstein MH, Barakat RR, Chi DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer 2008; 18:1065.</a></li><li><a class="nounderline abstract_t">Oduyebo T, Rauh-Hain AJ, Meserve EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol 2014; 132:360.</a></li><li class="breakAll">Serrano C, Oduyebo T, Manola J, et al. Impact of tumor morcellation on the natural history of uterine leiomyosarcoma. Connective Tissue Oncology Society 2013. Poster 100. http://www.ctos.org/2013%20CTOS%20AM%20FP%20for%20Web.pdf (Accessed on May 21, 2014).</li><li class="breakAll">US Food and Drug Administration. Laparoscopic power morcellators. http://www.fda.gov/medical-devices/surgery-devices/laparoscopic-power-morcellators (Accessed on September 24, 2019).</li><li><a class="nounderline abstract_t">Seagle BL, Sobecki-Rausch J, Strohl AE, et al. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecol Oncol 2017; 145:61.</a></li><li><a class="nounderline abstract_t">Leitao MM Jr, Zivanovic O, Chi DS, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol 2012; 125:409.</a></li><li><a class="nounderline abstract_t">Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 1993; 50:105.</a></li><li><a class="nounderline abstract_t">Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 2003; 91:209.</a></li><li><a class="nounderline abstract_t">Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993; 71:1702.</a></li><li><a class="nounderline abstract_t">Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008; 112:820.</a></li><li><a class="nounderline abstract_t">Sandruck J, Escobar P, Lurain J, Fishman D. Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature. Gynecol Oncol 2004; 92:701.</a></li><li class="breakAll">Engle DB, Smiley LM, Baum SL, Wellman GP.  Positron Emission Tomography in detection of metastatic leiomyosarcoma in a postoperative patient: a case report. Proc Obstet Gynecol. 2011 July;2(1):Article 14[5 p]. ir.uiowa.edu/cgi/viewcontent.cgi?article=1111&amp;context=pog (Accessed on August 15, 2012).</li><li><a class="nounderline abstract_t">Sung PL, Chen YJ, Liu RS, et al. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas. Eur J Gynaecol Oncol 2008; 29:246.</a></li><li class="breakAll">Corpus Uteri. In: AJCC Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.403.</li><li><a class="nounderline abstract_t">Zivanovic O, Leitao MM, Iasonos A, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol 2009; 27:2066.</a></li><li><a class="nounderline abstract_t">Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985; 3:1240.</a></li><li><a class="nounderline abstract_t">Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 2009; 112:563.</a></li><li><a class="nounderline abstract_t">Hensley ML, Wathen K, Maki RG, et al. Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. J Clin Oncol 2010; 28S: ASCO #10021.</a></li><li><a class="nounderline abstract_t">Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44:808.</a></li><li><a class="nounderline abstract_t">Hensley ML, Enserro D, Hatcher H, et al. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2018; :JCO1800454.</a></li><li><a class="nounderline abstract_t">Littell RD, Tucker LY, Raine-Bennett T, et al. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes. Gynecol Oncol 2017; 147:11.</a></li><li><a class="nounderline abstract_t">Hensley ML. Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there". Gynecol Oncol 2017; 147:1.</a></li><li><a class="nounderline abstract_t">Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013; 119:1555.</a></li><li><a class="nounderline abstract_t">Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients. J Clin Oncol 2011; 29S: ASCO #10022.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Uterine cancer. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (Accessed on May 05, 2020).</li><li><a class="nounderline abstract_t">Zivanovic O, Jacks LM, Iasonos A, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012; 118:660.</a></li><li><a class="nounderline abstract_t">Iasonos A, Keung EZ, Zivanovic O, et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer 2013; 119:1816.</a></li><li><a class="nounderline abstract_t">Chudasama P, Mughal SS, Sanders MA, et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 2018; 9:144.</a></li><li><a class="nounderline abstract_t">Ben-Ami E, Barysauskas CM, Solomon S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer 2017; 123:3285.</a></li><li><a class="nounderline abstract_t">Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18:1493.</a></li><li><a class="nounderline abstract_t">Hensley ML, Chavan SS, Solit DB, et al. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clin Cancer Res 2020; 26:3881.</a></li><li><a class="nounderline abstract_t">Busca A, Parra-Herran C. Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis. Adv Anat Pathol 2017; 24:354.</a></li><li><a class="nounderline abstract_t">Hoang L, Chiang S, Lee CH. Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology 2018; 50:162.</a></li><li><a class="nounderline abstract_t">Leitao MM Jr, Hensley ML, Barakat RR, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol 2012; 124:558.</a></li><li><a class="nounderline abstract_t">Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 2004; 12:338.</a></li><li><a class="nounderline abstract_t">Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004; 101:1455.</a></li><li><a class="nounderline abstract_t">Anraku M, Yokoi K, Nakagawa K, et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg 2004; 127:1107.</a></li><li><a class="nounderline abstract_t">Burt BM, Ocejo S, Mery CM, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg 2011; 92:1202.</a></li><li><a class="nounderline abstract_t">Clavero JM, Deschamps C, Cassivi SD, et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg 2006; 81:2004.</a></li><li class="breakAll">O'Cearbhaill RE, Maki RG, Zheng J, et al. Evaluation of the role of thermal ablation in the treatment of soft tissue sarcomas. 2009 Connective Tissue Oncology Society Meeting, Miami, FL. #39259.</li><li><a class="nounderline abstract_t">Díaz-Montes TP, El-Sharkawy F, Lynam S, et al. Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma. Int J Gynecol Cancer 2018; 28:1130.</a></li><li><a class="nounderline abstract_t">Moskovic E, MacSweeney E, Law M, Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993; 66:1009.</a></li><li><a class="nounderline abstract_t">Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 2005; 97:624.</a></li><li><a class="nounderline abstract_t">Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25:2755.</a></li><li><a class="nounderline abstract_t">Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:329.</a></li><li><a class="nounderline abstract_t">Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008; 109:323.</a></li><li><a class="nounderline abstract_t">Hensley ML, Miller A, O'Malley DM, et al. A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): A Gynecologic Oncology Group study. Gynecol Oncol 2014; 133S: SGO #SP-2.</a></li><li><a class="nounderline abstract_t">Seddon BM, Whelan J, Strauss SJ, et al. GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol 2015; 33S: ASCO #10500.</a></li><li><a class="nounderline abstract_t">Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55:1648.</a></li><li><a class="nounderline abstract_t">Pautier P, Italiano A, Piperno-Neumann S, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2022; 23:1044.</a></li><li><a class="nounderline abstract_t">Sutton G, Blessing J, Hanjani P, et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 96:749.</a></li><li><a class="nounderline abstract_t">Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 2004; 92:644.</a></li><li><a class="nounderline abstract_t">Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166:556.</a></li><li><a class="nounderline abstract_t">Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62:226.</a></li><li><a class="nounderline abstract_t">Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 2016; 34:786.</a></li><li><a class="nounderline abstract_t">Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012; 124:48.</a></li><li><a class="nounderline abstract_t">Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol 2011; 123:553.</a></li><li><a class="nounderline abstract_t">Pautier P, Floquet A, Chevreau C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015; 16:457.</a></li><li><a class="nounderline abstract_t">Martin-Broto J, Pousa AL, de Las Peñas R, et al. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. J Clin Oncol 2016; 34:2294.</a></li><li><a class="nounderline abstract_t">Gadducci A, Grosso F, Scambia G, et al. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. Br J Cancer 2018; 119:565.</a></li><li><a class="nounderline abstract_t">García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29:2528.</a></li><li><a class="nounderline abstract_t">Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005; 98:99.</a></li><li><a class="nounderline abstract_t">Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104:1706.</a></li><li><a class="nounderline abstract_t">van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.</a></li><li><a class="nounderline abstract_t">Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387:1629.</a></li><li><a class="nounderline abstract_t">Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009; 115:466.</a></li><li><a class="nounderline abstract_t">Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007; 110:518.</a></li><li><a class="nounderline abstract_t">O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 2010; 116:424.</a></li><li><a class="nounderline abstract_t">George S, Feng Y, Manola J, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 2014; 120:738.</a></li><li><a class="nounderline abstract_t">Edmondson RJ, O'Connell RL, Banerjee S, et al. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecol Oncol 2021; 163:524.</a></li></ol></div><div id="topicVersionRevision">Topic 3188 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19853898" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Uterine sarcomas: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798712" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459493" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860468" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506484" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766261" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646120" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986239" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24296345" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24296345" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24296345" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28317559" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22366592" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8349151" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14529683" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381710" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18189292" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766270" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766270" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18592788" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18592788" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255317" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3897471" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135708" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378136" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289732" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28747255" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28923359" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335221" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21751199" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23456762" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321523" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Integrative genomic and transcriptomic analysis of leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28440953" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988646" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299819" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28787279" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275929" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085894" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536333" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316901" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15052209" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21867989" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731120" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731120" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29975291" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8281375" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863170" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602081" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534250" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18394689" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): A Gynecologic Oncology Group study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3884128" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35835135" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721421" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766260" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536229" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8751554" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371143" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21996263" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917307" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795402" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27185843" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057406" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606430" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15916799" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Temozolomide in uterine leiomyosarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134177" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595799" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26874885" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767065" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666649" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19932916" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222211" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34625284" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
